Regeneron Pharmaceuticals (REGN) Profit Margin History

Historical gross, operating and net quarterly profit margin for Regeneron Pharmaceuticals (REGN) over the last 10 years. The current net profit margin for Regeneron Pharmaceuticals as of January 22, 2018 is 23.17%.

Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $40.382B $4.860B
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens.